Japan Brain Cancer Therapeutics Market

Japan Brain Cancer Therapeutics Market Executive Summary

Japan Brain Cancer Therapeutics Market valued at $143 Mn in 2022, projected to reach $332 Mn by 2030 with a 11.1% CAGR.

The abnormal growth of brain cells serves as an indicator of brain cancer, wherein these cells display characteristics that can be either malignant (cancerous) or benign (non-cancerous). Although the precise cause of brain cancer remains unclear, recognized risk factors encompass exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor consist of headaches, gradual sensory decline, balance issues, speech impediments, and hearing difficulties. The presentation of these symptoms varies depending on factors like the tumor’s size, location, and growth rate. Treatment strategies for brain cancer are determined by the tumor’s type, location, and size, with frequently employed methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the utilization of carmustine implants.

As of the latest projections, by the year 2050, the prevalence of cancer in Japan is anticipated to reach 3,665,900 cases, marking a 13.1% increase from the figures recorded in 2020. For the year 2023, approximately 1,700 new cases of brain and nervous system cancer were seen, contributing to a 5-year prevalent case count of 5,900. Colorectal, stomach, lung, prostate, and female breast cancers emerge as the most common types, collectively constituting around 60% of all cancer cases in the country. Specifically focusing on brain and nervous system cancers, Japan reported 2,800 new cases, with the age-standardized incidence rate increasing from 9.89/100,000 to 12.14/100,000 and an estimated annual percentage change (EAPC) of 0.69.

Daiichi Sankyo, a prominent pharmaceutical company based in Japan, has recently introduced Delytact, the world's first oncolytic virus therapy, designed for the treatment of malignant glioma, a form of brain cancer. As the first of its kind to be introduced globally, this innovative therapy achieved a major milestone when it was granted conditional approval by Japan's Ministry of Health, Labour and Welfare (MHLW). Daiichi Sankyo must carry out post-marketing assessments to compile safety and efficacy information for Delytact as part of the approval requirements. Concurrently, other Japanese pharmaceutical companies, like Astellas and Kissei Pharmaceutical, have entered into international collaborations and licensing arrangements to aid in the creation of medications for the treatment of brain cancer. Additionally, Taiho Pharmaceutical, renowned for its research in oral anticancer drugs, boasts a robust development pipeline, culminating in the approval of futibatinib for marketing in the United States.

Market Dynamics

Market Growth Drivers

Rising Incidence and Ageing Population: Brain tumors are becoming more common in Japan, especially in older adults who are more susceptible. Japan possesses the world's most-aged population, featuring the largest percentage of individuals aged 80 and older, accounting for 11.1% in the year 2023. This change in demographics leads to a larger pool of possible patients. Additionally, the upward trend is bolstered by the rising life expectancy, as individuals diagnosed with brain cancer experience prolonged survival owing to advancements in treatment methods.

Advancements in Treatment Options: The development of innovative medicines for brain-related disorders and technological advances in the healthcare industry are improving the effectiveness of treatments, which in turn is driving market expansion. The introduction of novel and efficacious treatments frequently results in a surge in the demand for these therapies. As the market expands, it attracts further investment, fostering a cycle of innovation, demand, and growth within the healthcare industry.

Pharmaceutical Research and Development: The market for brain tumor therapy is expected to be stimulated by the increase in funding going toward pharmaceutical research & development, both globally and in Japan specifically. Data indicates that Japan spends 11.5% of GDP on healthcare, more than the OECD average of 9.2%. This increased commitment to healthcare expenditure, particularly in research and development, acts as a potent driver for market growth in the field of brain tumor therapy.

Market Restraints

High Cost of Treatment: The substantial costs associated with advanced treatments such as targeted drugs and immunotherapies pose a financial challenge for both patients and the healthcare system. Financial hardship may be exacerbated by access to these expensive treatments being hampered by complex payment processes or inadequate insurance coverage. As a result, gaps in treatment availability due to socioeconomic reasons could appear, raising ethical questions about the equitable distribution of healthcare.

Limited Efficacy of Current Treatments: The effectiveness of current treatments for brain cancer might be constrained, emphasizing the necessity for groundbreaking innovations to markedly enhance patient outcomes. This constraint could potentially influence the market prospects of presently available drugs.

Regulatory Hurdles: The rigorous regulatory demands and approval procedures may present obstacles in the development and introduction of novel drugs for brain cancer treatment, potentially causing delays in their market entry.

Healthcare Policies and Regulatory Landscape

In Japan, the regulatory landscape for treatment drugs is governed by the Pharmaceuticals and Medical Devices Agency (PMDA), which evaluates the safety, efficacy, and quality of pharmaceuticals, including treatment drugs, before their market approval. Collaborating with the PMDA, the Ministry of Health, Labor and Welfare (MHLW) plays a pivotal role in setting healthcare policies and ensuring drugs adhere to national health standards. Conditional approvals may be granted based on early-stage results, with companies mandated to conduct post-marketing evaluations to gather additional data on drug efficacy and safety. The MHLW oversees the national health insurance system, influencing coverage and reimbursement policies for treatment drugs. Japanese pharmaceutical companies often enter global partnerships and licensing agreements to facilitate international collaboration on drug development and distribution.

Competitive Landscape

Key Players

• Roche
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol Myers Squibb
• Eli Lilly
• Sanofi
• Johnson & Johnson
• Takeda